MeSH D000740 - anemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006402:Hematologic diseases
D000740:Â
Anemia
D000741:Aplastic anemia
D000743:Hemolytic anemia
D000747:Hypochromic anemia
0 Companies
0 Drugs
Success rate
D000748:Macrocytic anemia
0 Companies
0 Drugs
Success rate
D000750:Myelophthisic anemia
0 Companies
0 Drugs
Success rate
D000751:Neonatal anemia
0 Companies
0 Drugs
Success rate
D000753:Refractory anemia
D000756:Sideroblastic anemia
D012010:Pure red-cell aplasia
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Epoetin theta | Biopoin |  | 2009-10-23 |  |  |
| Roche | Methoxy polyethylene glycol-epoetin beta | Mircera |  | 2007-07-20 | $496.403 M | Q4/22-Q3/23 |
| Epoetin beta | NeoRecormon |  | 1997-07-16 |  |  | |
| Sandoz | Epoetin alfa | Binocrit |  | 2007-08-28 |  |  |
| Organon | Nandrolone | Durabolin |  | 1982-01-01 |  |  |
| Pfizer | Epoetin zeta | Retacrit |  | 2007-12-18 | $340 M | Y2023 |
| Voxelotor | Oxbryta |  | 2022-02-14 | $328 M | Y2023 | |
| Takeda | Ferumoxytol | Rienso |  | 2012-06-15 |  |  |
| Bristol Myers Squibb | Luspatercept | Reblozyl |  | 2020-06-25 | $1,897 M | Q2/24-Q1/25 |
| Astellas Pharma | Roxadustat | Evrenzo |  | 2021-08-18 |  |  |
| Woodward Pharma Services | Nandrolone decanoate | Deca-durabolin |  | 1986-06-12 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
46%61/132
Phase 2
50%55/109
Phase 3
53%54/101
Approved: 17Overall Success rate: 12%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use